Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[LAK cells and cancer].

T Taguchi, Y Kimoto

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |December 1, 1986
    PubMed
    Summary

    Lymphokine-activated killer (LAK) cells effectively target malignant tumors. Adoptive immunotherapy with LAK cells and interleukin-2 (IL-2) shows promise, with modified protocols reducing toxic side effects for safer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    [Correlation of DBA lectin binding and malignancy in breast cancers: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    Pokeweed mitogen induces p55 interleukin-2 receptor expression on human monocytes and its effect on interleukin-2 activated monocyte cytotoxicity.

    Immunological investigations·1992
    Same author

    [Athyreotic congenital hypothyroidism in two sisters].

    Nihon Naibunpi Gakkai zasshi·1992
    Same author

    Immunological identification of a Cl- channel protein in electric organs of Narke japonica.

    Biochemical and biophysical research communications·1992
    Same author

    DNA synthesis and related enzymes altered in compensatory lung growth in rats.

    Scandinavian journal of clinical and laboratory investigation·1992

    Area of Science:

    • Immunology
    • Oncology

    Context:

    • Malignant tumors present a significant therapeutic challenge.
    • Adoptive immunotherapy is an emerging cancer treatment strategy.

    Purpose:

    • To evaluate the efficacy of lymphokine-activated killer (LAK) cells in combating malignant tumors.
    • To investigate the role of interleukin-2 (IL-2) in enhancing LAK cell activity.
    • To assess the safety and effectiveness of LAK cell-based immunotherapy.

    Summary:

    • Lymphokine-activated killer (LAK) cells, derived from lymphocytes cultured with interleukin-2 (IL-2), exhibit non-specific cytotoxic activity against malignant cells.
    • Combination therapy with IL-2 potentiates LAK cell efficacy.
    • Clinical applications in the USA have demonstrated complete regression of malignant melanoma metastases and partial responses in other cancers.
    • High-dose IL-2 can cause capillary leak syndrome, a significant toxic side effect.
    • Our research indicates that LAK cells incubated for 1-2 weeks require lower IL-2 concentrations, enabling safer adoptive immunotherapy.

    Impact:

    • This research offers a potentially safer and effective immunotherapy approach for various malignancies.
    • Optimized LAK cell therapy protocols could improve patient outcomes and reduce treatment-related toxicity.
    • The findings contribute to the advancement of adoptive cell therapies in oncology.

    Related Experiment Videos